CompletedPhase 3NCT04204096
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
Studying Typhoid
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- International Vaccine Institute
- Principal Investigator
- Josefina C Carlos, MDUniversity of the East-Ramon Magsaysay Memorial Medical Center Inc.
- Intervention
- Vi-DT (Multi-dose formulation)(biological)
- Enrollment
- 1800 target
- Eligibility
- 45 years · All sexes
- Timeline
- 2020 – 2021
Study locations (4)
- Lingga Health Research Center, Calamba, Laguna, Philippines
- Magcase Health Center, San Pablo, Laguna, Philippines
- Putatan Research Center, Muntinlupa, National Capital Region, Philippines
- University of the Philippines Manila-National Institutes of Health, Manila, Philippines
Collaborators
SK Bioscience Co., Ltd. · Bill and Melinda Gates Foundation
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04204096 on ClinicalTrials.govOther trials for Typhoid
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGEARLY PHASE1NCT04083950Induction of Gut Permeability by an Oral VaccineUSDA, Western Human Nutrition Research Center
- ACTIVE NOT RECRUITINGPHASE3NCT03299426Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, MalawiUniversity of Maryland, Baltimore
- ACTIVE NOT RECRUITINGPHASE4NCT03970304CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated AdultsUniversity of Maryland, Baltimore